NCT04371367

Avdoralimab an Anti-C5aR Antibody, in Patients With COVID-19 Severe Pneumonia ( FORCE )

A Double-blind, Randomized Study Versus Placebo of Avdoralimab (IPH5401), an Anti-C5aR Antibody, in Patients With COVID-19 Severe Pneumonia

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 208 (actual)
• Sponsor: Assistance Publique Hopitaux De Marseille · Academic / Other
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

The primary objective of this trial is to improve the proportion of COVID-19 patients with severe pneumonia who no longer need to be hospitalized, and to reduce the need for and duration of mechanical ventilation in patients with COVID-19 pneumonia complicated by acute respiratory distress syndrome (ARDS).

Conditions

• COVID

Interventions

Type	Name	Description
BIOLOGICAL	avdoralimab	intravenous administration of avdoralimab
OTHER	Placebo	intravenous administration of placebo

Timeline

• Start date: 2020-04-27
• Primary completion: 2021-03-30
• Completion: 2021-03-30
• First posted: 2020-05-01
• Last updated: 2021-05-27

Locations

1 site across 1 country: France